Treatment and survival patterns for germ cell tumors among 13- to 24-year olds in Yorkshire, UK

Pediatric Blood and Cancer

Volumn 56, Issue 2, 2011, Pages 282-288

  Feltbower, Richard G ^a   Siller, Catherine ^b   Woodward, Emma ^b   McKinney, Patricia A ^a   Picton, Susan V ^c   Joffe, Jonathan ^d   Stark, Daniel P ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^d CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chemotherapy; Germ cell tumor; Survival; Teenager; Young adult

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; FEMALE; FOLLOW UP; GERM CELL TUMOR; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PATIENT CARE; PRIORITY JOURNAL; SURVIVAL RATE; TESTIS CANCER; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; RADIOTHERAPY; TESTICULAR NEOPLASMS; UROGENITAL SURGICAL PROCEDURES; YOUNG ADULT;

EID: 78650140972     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22794     Document Type: Article

References (26)

1. National Collaborating Centre for Cancer. Guidance on cancer services, improving outcomes in children and young people with cancer. London: National Institute for Health and Clinical Excellence; 2005.
2. Whelan J, Dolbear C, Mak V, et al. Where do teenagers and young adults receive treatment for cancer? J Pub Health 2007; 29: 178-182.
3. Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: Carboplatinum, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000; 18: 3809-3818.
4. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 1993; 11: 598-606.
5. Bokemeyer C, Kohrmann O, Tischler J, et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol 1996; 7: 1015-1021.
6. Horwich A, Sleijfer DT, Fossåa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 1997; 15: 1844-1852.
7. Clemm C, Bokemeyer C, Gerl A, et al. Randomized trial comparing cisplatin/etoposide/ifosfamide with carboplatin monochemotherapy in patients with advanced metastatic seminoma. Proc Am Soc Clin Oncol 2000; 19: 328 (abstract 1283).
8. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol 2007; 25: 2938-2943.
9. Feltbower RG, McNally RJ, Kinsey SE, et al. Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990-2000. Eur J Cancer 2008; 45: 420-427.
10. Feltbower RG, Lewis IJ, Picton S, et al. Diagnosing childhood cancer in primary care-A realistic expectation? Br J Cancer 2004; 90: 1882-1884.
11. Feltbower RG, Picton S, Bridges LR, et al. The epidemiology of childhood and young adult central nervous system tumors in Yorkshire, UK. Pediatr Hematol Oncol 2004; 21: 647-660.
12. Birch JM, Alston RD, Kelsey AM, et al. Classification and incidence of cancers in adolescents and young adults in England 1979-1997. Br J Cancer 2002; 87: 1267-1274.
13. Baxter GM, Sidhu PS. Ultrasound of the urogenital system. New York: Thieme Medical Pub; 2000.
14. The International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
15. StataCorp. Stata Release 10. Texas: College Station; 2007.
16. Pearce MS, Parker L, Windebank KP, et al. Cancer in adolescents and young adults aged 15-24 years: A report from the North of England Young Person's Malignant Disease Registry, UK. Pediatr Blood Cancer 2005; 45: 687-693.
17. Møller H, Evans H. Epidemiology of gonadal germ cell tumors in males and females. APMIS 2003; 111: 43-48.
18. Alston RD, Rowan S, Eden TO, et al. Cancer incidence patterns by region and socioeconomic deprivation in teenagers and young adults in England. Br J Cancer 2007; 96: 1760-1766.
19. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol 2008; 53: 478-496.
20. Birch JM, Pang D, Alston RD, et al. Survival from cancer in teenagers and young adults in England, 1979-2003. Br J Cancer 2008; 99: 830-835.
21. Toner GC, Stockler MR, Boyer MJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumors: A randomized trial-Australian and New Zealand Germ Cell Trial Group. Lancet 2001; 357: 739-745.
22. Rogers PC, Olson TA, Cullen JW, et al. Treatment of children and adolescents with stage ii testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study-Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol 2004; 22: 3563-3569.
23. de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15: 1837-1843.
24. Loehrer PJ, Sr., Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13: 470-476.
25. Frazier AL, Rumcheva P, Olson T, et al. Children's Oncology Group. Pediatr Blood Cancer 2008; 50: 746-751.
26. Palmer RD, Barbosa-Morais NL, Gooding EL, et al. Children's Cancer and Leukaemia Group. Pediatric malignant germ cell tumors show characteristic transcriptome profiles. Cancer Res 2008; 68: 4239-4247.